

SPECIAL ARTICLE

Staging in bipolar disorder: from theoretical framework to clinical utility

Michael Berk¹⁻⁵, Robert Post⁶, Aswin Ratheesh^{3,4}, Emma Gliddon¹, Ajeet Singh¹, Eduard Vieta⁷, Andre F. Carvalho^{8,9}, Melanie M. Ashton¹, Lesley Berk^{1,2}, Susan M. Cotton^{3,4}, Patrick D. McGorry^{3,4}, Brisa S. Fernandes¹, Lakshmi N. Yatham¹⁰, Seetal Dodd¹⁻³

¹IMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, Australia; ²Department of Psychiatry, University of Melbourne, Melbourne, Australia; ³Orygen, the National Centre of Excellence in Youth Mental Health, Parkville, Australia; ⁴Centre for Youth Mental Health, University of Melbourne, Melbourne, Australia; ⁵Florey Institute for Neuroscience and Mental Health, Melbourne, Australia; ⁶Department of Psychiatry and Behavioral Sciences, George Washington University School of Medicine and Health Sciences, Washington, DC, USA; ⁷Bipolar Disorders Program, Department of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain; ⁸Translational Psychiatry Research Group and Department of Clinical Medicine, Federal University of Ceará, Fortaleza, Brazil; ⁹Institute for Clinical Research and Education in Medicine, Padua, Italy; ¹⁰Department of Psychiatry, University of British Columbia, Vancouver, Canada

Illness staging is widely utilized in several medical disciplines to help predict course or prognosis, and optimize treatment. Staging models in psychiatry in general, and bipolar disorder in particular, depend on the premise that psychopathology moves along a predictable path: an at-risk or latency stage, a prodrome progressing to a first clinical threshold episode, and one or more recurrences with the potential to revert or progress to late or end-stage manifestations. The utility and validity of a staging model for bipolar disorder depend on its linking to clinical outcome, treatment response and neurobiological measures. These include progressive biochemical, neuroimaging and cognitive changes, and potentially stage-specific differences in response to pharmacological and psychosocial treatments. Mechanistically, staging models imply the presence of an active disease process that, if not remediated, can lead to neuroprogression, a more malignant disease course and functional deterioration. Biological elements thought to be operative in bipolar disorder include a genetic diathesis, physical and psychic trauma, epigenetic changes, altered neurogenesis and apoptosis, mitochondrial dysfunction, inflammation, and oxidative stress. Many available agents, such as lithium, have effects on these targets. Staging models also suggest the utility of stage-specific treatment approaches that may not only target symptom reduction, but also impede illness neuroprogression. These treatment approaches range from prevention for at-risk individuals, to early intervention strategies for prodromal and newly diagnosed individuals, complex combination therapy for rapidly recurrent illness, and palliative-type approaches for those at chronic, late stages of illness. There is hope that prompt initiation of potentially disease modifying therapies may preclude or attenuate the cognitive and structural changes seen in the later stages of bipolar disorder. The aims of this paper are to: a) explore the current level of evidence supporting the descriptive staging of the syndromal pattern of bipolar disorder; b) describe preliminary attempts at validation; c) make recommendations for the direction of further studies; and d) provide a distillation of the potential clinical implications of staging in bipolar disorder within a broader transdiagnostic framework.

Key words: Bipolar disorder, clinical staging, early intervention, neuroprogression, neuroprotection, cognitive functioning, biological markers, kindling, treatment outcome, lithium, transdiagnostic framework

(World Psychiatry 2017;16:00–00)

Clinical staging models are extensively used in medicine, especially in oncology and cardiology, where they are major determinants of prognosis and drivers of treatment choice. The utility of staging in these specialties is aided by clear biomarkers of the staging process. In cancer, for example, the “tumour, node, metastasis” (TNM) model of disease staging uses three easily operationalized and objective domains.

In contrast, psychiatry, lacking objective markers, has not been able to empirically define the critical components of stage definitions. The field has tentatively begun to use staging models as a template to model the sequence of vulnerability, at-risk states, prodrome, onset, progression, and end-stage chronicity, and to link these to outcome and choice of specific treatments.

The body of data on this topic in bipolar disorder and other mental illnesses is steadily increasing^{1,2}, allowing closer examination of the evidence supporting or refuting the theoretical underpinnings of the construct, and refining its applicability to targeted and individualized diagnostic, prognostic and therapeutic domains.

The first hint supporting clinical staging in psychiatry came from Kraepelin³, whose detailed observations of the course of

mental disorders over time suggested that this might be a useful validator of diagnostic assignment. However, his hard and largely tactical distinction between dementia praecox and manic depressive illness proved to be an oversimplification, and he did not define therapeutically useful stages or patterns of illness.

A century later, Fava and Kellner⁴, focusing on mood and anxiety disorders, called staging the “neglected dimension in psychiatric classification”, presaging current developments. Staging of mental disorders was formalized and operationalized by McGorry et al⁵, who aimed to move beyond diagnostic silos to develop a widely used transdiagnostic model. Staging models have subsequently been adapted to bipolar disorder⁶⁻⁹, depression^{10,11}, eating disorders¹², and anxiety disorders such as agoraphobia¹³, where they share the same essential elements as the original models¹⁴.

It needs to be emphasized that the early stages of most of these syndromes are non-specific and overlapping, favouring the application of transdiagnostic models of staging¹⁵. Models which focus on traditional diagnostic categories are largely used to describe the syndromal patterns emerging after a first full-threshold episode.

Whether transdiagnostic or disorder-specific staging models are more appropriate for mental illness has been debated. The relative concentration of specific diagnoses in some family histories and the differences in course and treatment outcomes across disorders support the latter approach, while the lack of specificity of genetic and biomarker findings, the extensive comorbidity between disorders, the similarity in effective treatments, and the symptomatic overlap between several disorders lend support to the former approach¹⁶.

In broad terms, transdiagnostic staging models are probably optimal for the study of the at-risk and prodromal phases as a “trunk”, while disorder-specific models can contribute to the understanding of the later phenomenon of syndromally expressed “branches”. Individual psychiatric disorders, as currently defined, may not turn out to be discrete entities if and when their pathophysiology is identified, and are likely syndromal patterns only. Furthermore, the link between any syndromal phenotype and the underlying neurobiology remains tenuous¹⁷.

MODELS

Clinical staging describes where an individual's presentation can be placed on a temporal spectrum of disorder progression. Staging models in psychiatry have generally adopted the numerical system that is used in medical staging models, being operationalized to begin with stage 0 (defined as an at-risk or latency stage), followed by stage 1 (defined as a prodrome), stage 2 as a first episode, and stage 3 of single or multiple recurrence, and ending with stage 4 of chronic disease⁵.

This model captures the aggregate course and evolution of bipolar disorder (see Figure 1). However, some individuals may have a more severe and deteriorating presentation and course from the outset, while others may have an episodic illness with full inter-episode recovery. Linear stepwise progression through serial phases may not be applicable to the course of illness in all patients.

Moreover, developmental approaches examining the heterogeneity in evolution of bipolar disorder among youth at high familial risk have argued for different phases in the prodrome. Sleep disturbances, anxiety, psychotic symptoms, depression and impairments in cognition may be indicative of sub-stages prior to the onset of classical or mixed/psychotic mania¹⁸. Similarly, a definition of stages based on functioning has been developed to attempt to clarify the latter end of the staging spectrum, based on inter-episodic recovery, comorbidity and ability to live independently¹⁹.

These descriptions of clinical stages of bipolar disorder still need operationalization, specification of cut-off points, and consensus on terminology, and would greatly benefit from external validation through biomarkers.

This would ideally follow what has happened for cancer. First came the documentation of the progression from genetic and environmental vulnerability (including double hits) to precancerous histology to malignant lesions (small, localized to larger, more invasive) to metastases (local to distant, single to multiple). Then predictive validity was delineated by linking these descriptive stages of tumour progression to prognosis and outcome (1 and 5 years survival rates). Discriminant validity subsequently emerged from linking stages to the effectiveness or not of different treatments and to the correspondence




Figure 1 Staging in bipolar disorder. CBT – cognitive behaviour therapy, ACT – assertive community treatment

of numbers and sequences of somatic mutations (those driving cell replication and those reflecting loss of tumour suppressor factors) and other biological measures.

The attainment of many of the aforementioned steps in cancer is an aspiration for mental disorders²⁰. This would permit relating descriptive stages to prognosis and ultimately to variables like survival (loss of years of life expectancy). The best validation would come from linking stages to neurobiological alterations and effectiveness (or not) of specific treatments. The task ahead is therefore to cluster clinically observable phenomena and label them as identifiable stages, and then proceed with demonstrating reliability, validity and clinical utility²¹.

This model lends itself to further detailing and subdividing. For example, stage 0 could contain more refined characterization of risk based on genetic/familial loading; prenatal factors such as maternal infection or drug exposure; and perinatal factors such as infection, head trauma, neglect and psychosocial abuse. As vulnerability genes such as calcium voltage-gated channel subunit alpha1 C (CACNA1C) and others are better defined and validated, these could be incorporated into this stage.

TESTABLE HYPOTHESES

The model of staging begs the testable hypothesis that the natural history of the disorder progresses through an aggregate and stepwise temporal progression. If staging is to be clinically useful, it needs to demonstrate the same kinds of utility seen in medicine, particularly oncology and cardiology (i.e., to have clinical validity). It needs to be documented that treatments can be identified which have differential value across illness stages. Established examples in schizophrenia include the appropriate use of clozapine for the later stages of treatment, while atypical antipsychotics with a lower adverse event burden are used to treat acute symptoms in early and intermediate stages. Transdiagnostic approaches such as public health interventions, nutraceuticals, Internet-based self-help or indicated prevention could target asymptomatic or at-risk stages²².

The staging model for bipolar disorder assumes that treatments chosen for earlier stages should have a more favourable risk-benefit ratio than those used for the later stages. Furthermore, treatments suited for clear diagnostic categories, such as antipsychotic and mood stabilizing medications, are less justifiable in the earliest stages of illness, where psychotic symptoms or mood swings are not overtly manifest, and their efficacy has not been systematically assessed²³. Symptoms of psychological distress may be evident early in the illness course, and preliminary evidence supports intervention with psychotherapeutic strategies such as family-focused treatment for high-risk children with symptoms of depression, cyclothymia, and other specified and unspecified bipolar and related disorders²⁴. In these circumstances, low-risk medicines and

putative neuroprotective agents²⁵ may also be more appropriate in term of safety (see Figure 1), but ultimately demonstration of efficacy in these early stages is required²⁶. More evidence is needed to determine if prognosis would be more favourable with earlier diagnosis and intervention, as predicted.

FROM NEUROPROGRESSION TO NEUROPROTECTION

The elements of the progressive underlying neuropathology in bipolar disorder appear to include epigenetics, telomere shortening, inflammation, oxidative and nitrosative stress and mitochondrial dysfunction, leading to decreased neurotrophins and consequent deficient neurogenesis and increases in cell shrinkage and apoptosis, ultimately compromising neuronal function and structure. The construct of neuroprogression has been proposed to incorporate the influence of the operative biological elements on the progressive course and outcome of the disorder^{27,28}. The impact of neuroprogression may also go some way to explaining treatment non-responsiveness²⁹.

Social, psychological, environmental, behavioural, biological and genetic variables can be either risk or protective factors that interact in a complex and often unpredictable manner to mediate or moderate the process of disease progression. These factors vary from person to person within a disorder, and also may vary in terms of their impact on different stages. Some risk factors may operate across all stages and some may be stage-specific. For instance, physical or sexual abuse or early attachment disruption may increase risk for the onset phase of a disorder, substance abuse may be noxious across all stages, while adherence and engagement might positively impact by lowering the risk of progression to later stages and improving prognosis³⁰.

It is theoretically possible to modify an individual's trajectory of disease progression. Early intervention may have potential to alter the distribution of the stages in a given population over time^{5,6}. A premise of staging is to define the earliest potential intervention window at any stage of disease evolution in order to prevent progression to the more advanced stages of a disorder and even engage the "reverse gear" towards more benign earlier stages. A person may move from a resistant stage 4 phenotype to a clinically improved and responsive stage 3 pattern. Strategies include primary prevention for those at highest risk, effective intervention in heterotypic and homotypic prodromes (secondary prevention), and attempts at limiting later stages of illness progression (tertiary prevention)³¹ (see Figure 1).

The aspiration that appropriate therapy can both prevent neuroprogression and have neuroprotective effects is supported by observational studies indicating that lithium treatment might increase grey matter volume in hippocampus and cortex, increase the length of telomeres, prevent the accumulation of some medical comorbidities, and prevent the progression to

dementia³²⁻³⁴. While further evidence is needed, it is plausible that some agents (such as atypical antipsychotics) may avert episodes but may or may not secondarily prevent progression, while others such as lithium not only prevent episodes but might also impede neuroprogression³⁵.

Prevention of disease progression (i.e., stopping episodes) may differ mechanistically and prognostically from an impact on neuroprogression. As a recent example, lithium and quetiapine were compared in the first year following a first episode of psychotic mania, and lithium but not quetiapine was associated with both decreases in manic and depressive episodes and protection against white matter changes over that time period³⁶. Observational data similarly suggest that lithium use may be associated with a greater protective effect on thalamic and grey matter volume than other mood stabilizers³⁷.

It is noteworthy that medications widely used for bipolar disorder – including lithium, valproate and some antipsychotics – appear to influence inflammation, oxidative biology, neurotrophins, neurogenesis and apoptosis³⁸. However, a new generation of medications that may more specifically target these pathways are being investigated, including erythropoietin, minocycline, N-acetylcysteine and anti-inflammatory agents³⁹. Agents more specifically acting on epigenetic mechanisms may also become viable therapeutic options for bipolar disorder, as they have in oncology⁴⁰.

THEORETICAL PREMISES UNDERPINNING THE STAGING MODEL

Post et al¹¹ defined the constructs of sensitization and kindling to capture and describe the progression of bipolar disorder. That model incorporated an increase in primary pathological factors and a failure of endogenous compensatory mechanisms associated with illness progression. Kindled seizure episodes progress from early partial seizures to full blown seizures triggered by stimulation of the amygdala to seizures that occur spontaneously. Here, stage-specific anticonvulsant medications are clearly delineated, with some agents and not others working on the initial stages of seizure development, middle stages of triggered seizures, or late stage spontaneous seizures.

The construct of allostatic load, pioneered by McEwen and Stellar⁴¹, was adapted to bipolar disorder by Kapczinski et al⁴². Allostatic load is the accumulated attempts to re-establish homeostasis after perturbations caused by, for example, stressors and abused substances. The compensatory adaptations required to achieve the new balance are generated at a cost to the organism. More stressors, mood episodes, and bouts of substance use provoke further adaptations, increasing allostatic load. This can generate a potential vicious cycle which can further impact brain circuits required for mood regulation and cognition and amplify vulnerability to recurrent episodes of illness. As an example, cortisol dysregulation could play a role in both the primary pathology and allostatic adaptations,

leading to illness progression and cognitive dysfunction⁴³. Gut dysbiosis may play a role in these inflammatory processes⁴⁴, although evidence for bipolar disorder remains limited⁴⁵.

WHAT IS THE EVIDENCE SUPPORTING STAGING?

The evidence supporting the descriptive components of staging in bipolar disorder is initially derived from observational studies of the course and natural history of the illness. Kraepelin was the first to observe that, with each successive episode, periods of euthymia in people with bipolar disorder become shorter³. His seminal observations have been repeatedly verified. More recent data derived from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study support the utility of staging, as the number of episodes was positively associated with more severe mania and depression, and poorer functioning and quality of life⁴⁶.

Considerable evidence supports the view in psychosis that: a) treatment earlier in the full-blown illness (i.e., after a shorter duration of untreated psychosis) is more effective; b) continuous treatment may be more effective than intermittent treatment; and c) response to an antipsychotic medicine decreases as the number of medication trials increases⁴⁷.

Similar evidence exists for lithium in bipolar disorder, as this medication is generally more effective if used earlier in the illness course, and response is poorer in those with multiple prior episodes. A number of observational studies have suggested that the efficacy of lithium declines with successive episodes⁴⁸⁻⁵⁰. A similar pattern appears to occur with atypical antipsychotics in the treatment of bipolar disorder, with data for both olanzapine⁵¹ and cariprazine⁵². Lamotrigine is less effective as a function of the number of prior depressive episodes, and so is treatment in general⁵³.

A cross-sectional examination of differences in medication prescription patterns found that monotherapy was common in stage 1, two drug combinations were common in stage 2, while the later stages were characterized by polypharmacy, with social and occupational functioning inversely correlated with number of medications⁵⁴.

The pattern seen in pharmacological studies is also seen in studies of psychological treatments for bipolar disorder. In one of the largest trials of cognitive behaviour therapy (CBT) for this disorder to date, while negative on the primary outcome measure, the therapy was found in post-hoc analyses to be more effective in people who had the fewest prior episodes, but appeared to aggravate outcomes of those who had more than 30 episodes⁵⁵. Similarly, data from psychoeducation studies showed that participants who had the fewest prior episodes had the greatest benefit from the intervention^{27,56}.

Neuroimaging evidence also supports the staging construct. The available data suggest, although with some inconsistencies, that brain structure is relatively preserved during the early stages of bipolar disorder^{57,58}. It appears that progressive

structural changes develop as the disorder evolves⁵⁹. Among a cohort of individuals with a first episode of mania, ventricular size was comparable to controls, while individuals with recurrent illness had ventricular enlargement⁶⁰. Over time, there is also progressive loss of grey matter^{61,62} in those who have a recurrence compared with those who remain episode free⁵⁸.

Some studies show smaller amygdala and insular volumes among ultra-high risk individuals prior to a threshold first episode of mania, suggesting that these potentially represent vulnerability markers⁶³. Some of these differences may be neurodevelopmentally mediated and interact with neuroprogression⁶⁴.

A decline in cognition is apparent in bipolar disorder. Cognitive dysfunction is also a major driver of the functional disability seen in the disorder⁶⁵ and may correlate to some extent with the structural changes noted above. There is strong evidence that cognitive changes are associated with the number of prior episodes of illness^{66,67}. That the number of episodes determines the magnitude of cognitive impairment was confirmed in a prospective cohort study, which showed that those who had a recurrence of a mood episode within a year after a first manic episode continued to show cognitive impairment, while those who remained episode free had significant improvements in cognition, suggesting that early intervention has the potential to reverse cognitive deficits⁶⁸.

Further, in a study that compared cognitive functioning among people who had had a first, second and third episode, participants who had a first or second episode showed relatively preserved cognitive functioning compared to controls, but subjects with three or more episodes performed more poorly compared to both controls and early-episode bipolar patients⁵⁹. Another study found that cognition was significantly worse than healthy control groups only for persons with stage 3 (recurrent) or 4 (chronic, late illness) bipolar disorder, while it was not in those in earlier illness stages⁶⁹.

A combination of cognitive measures such as verbal intelligence and cognitive control, along with episode density and level of residual depressive symptoms, were the best predictors of classification of persons with bipolar disorder into those with good and poor function⁷⁰. Similarly, a cluster analytical study of a historical cohort identified two subgroups of persons with bipolar disorder categorized as early and late stages based on differences in their functioning, age of onset, number of episodes and time from the onset of their first episode⁷¹.

Overall, the use of such a “reduced” or simplified staging such as “good or poor” outcome or “early or late” stages in bipolar disorder is likely to most easily show relationships with neurobiological markers. However, to be truly useful, more refined definitions of sub-stages may be required to define relationships to neurobiological markers and association with clinical response.

Some biochemical alterations are putative markers of an underlying disease process. For example, measures of inflammation, in particularly cytokines, are among the most robustly established correlates of both depression and mania⁷². The first

study of biomarkers and staging found that pro-inflammatory cytokines, notably interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF α), were raised in both early and late stage participants, but the increase of TNF α was more accentuated in the late stage, while that of IL-6 was more marked in the early stage. Anti-inflammatory cytokines such as interleukin 10 (IL-10) were increased in the early stage, with no differences from controls in the late stage. Brain-derived neurotrophic factor (BDNF) levels were normal in the early stage but decreased in the late stage participants⁷³. There are further data showing that BDNF and TNF α could be useful peripheral blood biomarkers aiding in the discrimination of the early from the late stage of bipolar disorder with an accuracy of 0.95 and 0.96, respectively⁷⁴. The fact that patients at a later stage have lower levels of IL-6 possibly indicates underlying differences in inflammation or allostatic load⁷¹.

Stage dependent changes in redox markers have been studied, particularly the glutathione pathway, where the activity of glutathione reductase and glutathione transferase appeared increased in late stage participants⁷⁵. A recent study that examined the differences between those at early and later illness stages showed that matrix metalloproteinase 9 and soluble intracellular adhesion molecule (sICAM) levels were significantly different across stages, even when patients were euthymic⁷⁶. While these biomarkers were associated with measures of functioning, cognition and subthreshold symptoms, the gross separation of early and later stages offered a pragmatic first-pass system to categorize participants into meaningful subgroups for biomarker analyses.

Neurotrophins may similarly display stage-related changes, with normal levels found in the early stages of the disorder, and decreases later in the illness course^{73,77}.

It is unclear whether these stage-related changes in biomarkers – including neurotrophins, oxidative stress and inflammatory measures – reflect the primary progression of the disorder or the failure of adaptive homeostatic mechanisms.

CAVEATS AND LIMITATIONS

The biochemical, cognitive and structural markers highlighted in the previous section do not have replicated sensitivity and specificity, which limits their clinical utility. The operationalization of staging, therefore, remains a challenge.

The staging model is at this point heuristic, and remains an exploratory framework. In contrast to staging in medical illnesses, where anatomic extent and impact of the disease determine stage, staging models in psychiatry remain largely based on a course-based definition of illness, using number of episodes and relapse criteria in defining stages⁸. A clear limitation of a course-based approach is that some individuals can have a benign course of illness with excellent inter-episode functioning despite multiple episodes, while others have a seemingly malignant course from the outset⁷⁸. Any staging

model needs to account for the between-individual as well as the within-individual variability over time in people with bipolar disorder. Staging, therefore, is an aggregate construct.

The difficulties in defining boundaries between hypomania and mania, and between mood episodes in general, have been described as representing a challenge to the staging model^{79,80}, but could potentially be overcome with precise definitions and criteria. Furthermore, the question whether persons with hypomania and depression of varying severity fit into stages 1b or 2 needs further clarification.

Research exploring the staging model has been so far largely cross-sectional, while longitudinal prospective cohort studies are necessary. The moderating effects of personality and temperament, environmental influences such as societal networks and supports, and occupational and environmental resources, have not been adequately explored.

Furthermore, comorbid medical and psychiatric diseases are not currently incorporated in staging models, although they are drivers of outcome and an almost universal feature of most mental disorders. More detailed sub-staging of illness evolution could include the presence or absence of prominent comorbidities such as anxiety and substance abuse, psychosis and other phenotypes. Not only will this be appropriate to refine the relationship to neurobiological markers, but the descriptors of effective therapeutic strategies in those with and without these comorbidities remains to be better defined and is clearly an unmet need for the field.

IMPLICATIONS AND DIRECTIONS

There are a number of implications of the staging model. The presence of a demonstrable process of disease progression moving along a definable temporal trajectory suggests the presence of targets that could be amenable to intervention and a focus for health services and providers. The progressive evolution of clinical phenotypes implies that the best opportunity for effective treatment may be the earliest. The staging model therefore logically segues to that of early intervention and hence a transdiagnostic approach.

Intervention is theoretically possible at a public health level focusing on the general population through strategies operating on identified risks, as with smoking for heart disease and cancer prevention. For bipolar disorder, lifestyle, diet, exercise and well-being interventions, including meditation and mindfulness, could be employed at a public health level, taking into consideration that these would be of value across emerging clinical phenotypes and other non-communicable medical disorders⁸¹. Indicated prevention targeted to people identified as being at high risk is feasible, as is targeting the “at-risk” or ultra-high risk stage^{82,83}.

Some heterotypic prodromes are by definition non-specific, with inattention symptoms, substance use, mood lability, anxiety, depression, sleep symptoms and non-specific behavioural

change documented⁸⁴⁻⁸⁶, and these may require different interventions. Once a homotypic prodrome or syndrome occurs, with manic-like symptoms, especially when accompanied by added risk factors such as family history loading and psychosocial adversity in childhood, one is at extremely high risk for evolution to full-blown illness and other specified and unspecified bipolar and related disorders⁸⁷⁻⁸⁹. The morbidity and dysfunction accompanying other specified and unspecified bipolar and related disorders is considerable, and clearly deserves concerted therapeutic efforts.

An essential first step in preventing the progression of the disorder, therefore, is accurate and timely diagnosis. The diagnosis of bipolar disorder is complex, and the disorder is often initially misdiagnosed, since the diagnosis is predicated on the presence of mania, yet the index presentation is more commonly depression. Mania, and even more so hypomania, can be missed, as it is often not associated with subjective distress and easily misinterpreted or misattributed, for example, to substance abuse. Full-blown mania can present with psychosis and be difficult to distinguish from schizophrenia. The affective storm and extreme mood lability of borderline personality disorder is a frequent diagnostic confounder⁹⁰. Another set of confounders accompany childhood onset bipolar disorder, a diagnosis which appears more common in the US than in many other countries, where the disorder is rarely seen before late adolescence or early adulthood⁹¹. The delay to first treatment is inversely associated with an earlier age of onset of bipolar disorder, and both early onset and treatment delay are independent predictors of a poor outcome in adulthood.

There are very few clinical trials that use staging to stratify recruits. Conus et al⁹² compared chlorpromazine and olanzapine in a first-episode mania cohort. They found that there was a shorter time to stabilization with the atypical agent, an interesting finding given that the extant literature generally shows atypical and typical agents to have broadly similar efficacy in mania⁹². More recently, a first-episode mania cohort stabilized on lithium plus quetiapine was randomized to one-year continuation with either agent alone⁹³. Unlike head-to-head studies in non-stage stratified cohorts, where no major differences between these agents were seen⁹³, lithium was superior to quetiapine on most clinical measures. It remains uncertain whether this superiority of lithium over quetiapine reflects the effects of staging (i.e., treating early after the first episode), primary efficacy differences, or methodological factors. A few other studies have targeted the later stages of the disorder. Murray et al⁹⁴, for example, have developed online acceptance and commitment approaches to people with chronic stages of the disorder.

Early intervention promises to prevent or minimize the secondary consequences of recurrent episodes⁹⁵. Kessing et al⁹⁶ documented that randomization to two years of comprehensive, expert, special clinic treatment after a first manic hospitalization not only led to fewer relapses than treatment as usual for the first two years, but its effect persisted and was

magnified over the next four years (even though all patients received treatment as usual during those years). This is important evidence that early high-quality intervention can change the trajectory and course of illness for the better in the intermediate term, if not indefinitely. Further, early intervention at first episode has been shown to reverse cognitive deficits and preserve grey matter volumes, especially in those that remain episode free^{58,68}. Similar benefits of early intervention programs are documented in first-episode psychosis⁹⁷.

With multiple recurrences, relationship, employment and financial difficulties erode self-esteem, corrode supports and coping strategies, and lead to guilt and loss. These are powerful stressors that can further perpetuate and exacerbate the illness⁵⁵. As the disorder typically begins in adolescence or early adulthood, it interrupts critical emotional, educational and psychosocial developmental goals and milestones, again acting as a secondary stressor. The earlier the illness begins, the poorer the outcomes in adulthood are⁹¹.

Early intervention strategies should aim to minimize disruption to normal developmental trajectories. It is likely that multifaceted strategies will be required, ones that integrate effective psychopharmacology with stage-specific and evidence-based psychosocial interventions. New research is beginning to emphasize the value of cognitive remediation and vocational recovery for late stage illness⁹⁸. Given the impact of the disorder on families, and the secondary consequences of family dysfunction, assisting with family and caregiver support is invaluable⁹⁹⁻¹⁰¹.

Staging models can also encourage help-seeking and improve access. A critical avenue is via service reform, especially the creation of early intervention services¹⁰². They can also provide further impetus to study the efficacy of potential primary and secondary preventive strategies where evidence is so far scant¹⁰³. Education campaigns may help ill persons or those at risk to seek help in earlier stages, and service changes that welcome persons at earlier illness stages may lead more timely delivery of effective interventions.

There is a clear need to study which treatments actually work for the early stages. Delivering care for more persons at an earlier stage may lead to a better resolution for those who would otherwise be “pre-destined” to have an adverse illness course, and an amelioration of the course for those who would go on to develop later stages.

CONCLUSIONS

The staging model is supported by observations that, with some exceptions, the clinical course of untreated or poorly treated bipolar disorder evolves in a complex but progressive fashion. Poorer response to treatment (principally lithium) occurs in the later stages of illness, and preliminary biomarker data (primarily neuroimaging) supports stage-specific brain changes.

A fundamental proposition of the staging model is that early intervention is more effective and needs to be less complex than later intervention. Early intervention implies that optimal use of biological and psychosocial interventions in at-risk, prodromal, and first-episode phases of bipolar disorder could mitigate some of the clinical and neurobiological consequences of the illness. These include markers of neuroprogression such as brain volume loss and cognitive and medical impairment.

It is hoped that some effective therapies for preventing episodes might also be neuroprotective and reduce the medical burden and reduced life expectancy that accompanies bipolar disorder. Defining and validating the staging of bipolar disorder is part of ongoing research efforts to improve management of this too often destructive illness.

ACKNOWLEDGEMENTS

M. Berk is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (1059660). E. Vieta is supported by the Spanish Ministry of Economy and Competitiveness (PI15/00283) integrated into the Plan Nacional de I+D+I and co-funded by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional, CIBERSAM, and the Comissionat per a Universitats i Recerca del DIUE de la Generalitat de Catalunya (2014 SGR 398). S.M. Cotton is supported by a NHMRC Career Development Fellowship (APP1061998). P.D. McGorry is supported by a Senior Principal Research Fellowship from NHMRC Australia (ID: 1060996) and currently receives research support from the Colonial Foundation, National Institute of Mental Health, Stanley Medical Research Institute and the BROAD Institute.

REFERENCES

1. Cosci F, Fava GA. Staging of mental disorders: systematic review. *Psychother Psychosom* 2013;82:20-34.
2. Grande I, Berk M, Birmaher B et al. Bipolar disorder. *Lancet* 2016;387:1561-72.
3. Kraepelin E. *Psychiatrie: ein Lehrbuch für Studierende und Aerzte*. Leipzig: Barth, 1896.
4. Fava GA, Kellner R. Staging: a neglected dimension in psychiatric classification. *Acta Psychiatr Scand* 1993;87:225-30.
5. McGorry PD, Hickie IB, Yung AR et al. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. *Aust N Z J Psychiatry* 2006;40:616-22.
6. Berk M, Conus P, Lucas N et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. *Bipolar Disord* 2007;9:671-8.
7. Berk M, Hallam KT, McGorry PD. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. *J Affect Disord* 2007;100:279-81.
8. Kapczinski F, Dias VV, Kauer-Sant'Anna M et al. Clinical implications of a staging model for bipolar disorders. *Expert Rev Neurother* 2009;9:957-66.
9. Vieta E, Reinares M, Rosa AR. Staging bipolar disorder. *Neurotox Res* 2011;19:279-85.
10. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. *Neurosci Biobehav Rev* 2007;31:858-73.
11. Post RM, Rubinow DR, Ballenger JC. Conditioning and sensitization in the longitudinal course of affective illness. *Br J Psychiatry* 1986;149:191-201.
12. le Grange D, Loeb KL, Van Orman S et al. Bulimia nervosa in adolescents: a disorder in evolution? *Arch Pediatr Adolesc Med* 2004;158:478-82.
13. Fava GA, Rafanelli C, Tossani E et al. Agoraphobia is a disease: a tribute to Sir Martin Roth. *Psychother Psychosom* 2008;77:133-8.
14. Sperling RA, Aisen PS, Beckett LA et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011;7:280-92.

15. Hickie IB, Scott EM, Hermens DF et al. Applying clinical staging to young people who present for mental health care. *Early Interv Psychiatry* 2013; 7:31-43.
16. Duffy A, Malhi GS, Grof P. Do the trajectories of bipolar disorder and schizophrenia follow a universal staging model? *Can J Psychiatry* 2017; 62:115-22.
17. McGorry P, Keshavan M, Goldstone S et al. Biomarkers and clinical staging in psychiatry. *World Psychiatry* 2014;13:211-23.
18. Duffy A, Horrocks J, Doucette S et al. The developmental trajectory of bipolar disorder. *Br J Psychiatry* 2014;204:122-8.
19. Kapczinski F, Dias VV, Kauer-Sant'Anna M et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2009;33:1366-71.
20. Vieta E. Staging and psychosocial early intervention in bipolar disorder. *Lancet Psychiatry* 2015;2:483-5.
21. Kapczinski F, Magalhães PV, Balanzá-Martinez V et al. Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report. *Acta Psychiatr Scand* 2014;130:354-63.
22. Agius M, Goh C, Ulhaq S et al. The staging model in schizophrenia, and its clinical implications. *Psychiatr Danub* 2010;22:211-20.
23. Francey SM, Nelson B, Thompson A et al. Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. *Schizophr Res* 2010;119:1-10.
24. Miklowitz DJ, Schneek CD, Singh MK et al. Early intervention for symptomatic youth at risk for bipolar disorder: a randomized trial of family-focused therapy. *J Am Acad Child Adolesc Psychiatry* 2013;52:121-31.
25. Dodd S, Maes M, Anderson G et al. Putative neuroprotective agents in neuropsychiatric disorders. *Prog Neuropsychopharmacol Biol Psychiatry* 2013;42:135-45.
26. McGorry PD, Nelson B, Markulev C et al. Effect of omega-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. *JAMA Psychiatry* 2017;74:19-27.
27. Reinares M, Colom F, Rosa AR et al. The impact of staging bipolar disorder on treatment outcome of family psychoeducation. *J Affect Disord* 2010;123:81-6.
28. Macneil CA, Hasty M, Cotton S et al. Can a targeted psychological intervention be effective for young people following a first manic episode? Results from an 18-month pilot study. *Early Interv Psychiatry* 2012;6:380-8.
29. Berk M, Kapczinski F, Andreazza AC et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. *Neurosci Biobehav Rev* 2011;35:804-17.
30. McGorry PD, Nelson B, Goldstone S et al. Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders. *Can J Psychiatry* 2010;55:486-97.
31. Simeonsson RJ. Primary, secondary, and tertiary prevention in early intervention. *J Early Interv* 1991;15:124-34.
32. Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? *Bipolar Disord* 2010;12:87-94.
33. Morris G, Berk M. The putative use of lithium in Alzheimer's disease. *Curr Alzheimer Res* 2016;13:853-61.
34. Berk M, Conus P, Kapczinski F et al. From neuroprogression to neuroprotection: implications for clinical care. *Med J Aust* 2010;193(Suppl. 4): S36-40.
35. Berk M, Daglas R, Dandash O et al. Quetiapine v. lithium in the maintenance phase following a first episode of mania: randomised controlled trial. *Br J Psychiatry* (in press).
36. Berk M, Dandash O, Daglas R et al. Neuroprotection after a first episode of mania: a randomized controlled maintenance trial comparing the effects of lithium and quetiapine on grey and white matter volume. *Transl Psychiatry* 2017;7:e1011.
37. Hibar DP, Westlye LT, van Erp TG et al. Subcortical volumetric abnormalities in bipolar disorder. *Mol Psychiatry* 2016;21:1710-6.
38. Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. *Nat Neurosci* 2007;10:1089-93.
39. Miskowiak KW, Carvalho AF, Vieta E et al. Cognitive enhancement treatments for bipolar disorder: a systematic review and methodological recommendations. *Eur Neuropsychopharmacol* 2016;26:1541-61.
40. Post RM. Epigenetic basis of sensitization to stress, affective episodes, and stimulants: implications for illness progression and prevention. *Bipolar Disord* 2016;18:315-24.
41. McEwen BS, Stellar E. Stress and the individual. Mechanisms leading to disease. *Arch Intern Med* 1993;153:2093-101.
42. Kapczinski F, Vieta E, Andreazza AC et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. *Neurosci Biobehav Rev* 2008;32:675-92.
43. Watson S, Thompson JM, Ritchie JC et al. Neuropsychological impairment in bipolar disorder: the relationship with glucocorticoid receptor function. *Bipolar Disord* 2006;8:85-90.
44. Evans SJ, Bassis CM, Hein R et al. The gut microbiome composition associates with bipolar disorder and illness severity. *J Psychiatr Res* 2017;87:23-9.
45. Salagre E, Vieta E, Grande I. The visceral brain: bipolar disorder and microbiota. *Rev Psiquiatr Salud Ment* 2017;10:67-9.
46. Magalhaes PV, Dodd S, Nierenberg AA et al. Cumulative morbidity and prognostic staging of illness in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *Aust N Z J Psychiatry* 2012;46: 1058-67.
47. Davis J, Eyre H, Jacka FN et al. A review of vulnerability and risks for schizophrenia: beyond the two hit hypothesis. *Neurosci Biobehav Rev* 2016;65:185-94.
48. Gelenberg AJ, Kane JM, Keller MB et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. *N Engl J Med* 1989;321:1489-93.
49. Swann AC, Bowden CL, Calabrese JR et al. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. *Am J Psychiatry* 1999;156:1264-6.
50. Franchini L, Zanardi R, Smeraldi E et al. Early onset of lithium prophylaxis as a predictor of good long-term outcome. *Eur Arch Psychiatry Clin Neurosci* 1999;249:227-30.
51. Berk M, Brnabic A, Dodd S et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. *Bipolar Disord* 2011;13:87-98.
52. McIntyre RS, Earley W, Cheng-Tao C et al. Impact of the number of lifetime episodes on cariprazine efficacy in patients with bipolar mania. Presented at the 19th Conference of the International Society for Bipolar Disorders, Washington, May 2017.
53. Post RM, Weiss SR. Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders. *CNS Neurosci Ther* 2011;17:649-60.
54. Goi PD, Bückner J, Vianna-Sulzbach M et al. Pharmacological treatment and staging in bipolar disorder: evidence from clinical practice. *Rev Bras Psiquiatr* 2015;37:121-5.
55. Scott J, Paykel E, Morriss R et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. *Br J Psychiatry* 2006;188:313-20.
56. Colom F, Reinares M, Pacchiarotti I et al. Has number of previous episodes any effect on response to group psychoeducation in bipolar patients? A 5-year follow-up post hoc analysis. *Acta Neuropsychiatrica* 2010;22:50-3.
57. Lisy ME, Jarvis KB, DelBello MP et al. Progressive neurostructural changes in adolescent and adult patients with bipolar disorder. *Bipolar Disord* 2011;13:396-405.
58. Kozicky JM, McGirr A, Bond DJ et al. Neuroprogression and episode recurrence in bipolar I disorder: a study of gray matter volume changes in first-episode mania and association with clinical outcome. *Bipolar Disord* 2016;18:511-9.
59. Lopez-Jaramillo C, Lopera-Vásquez J, Gallo A et al. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. *Bipolar Disord* 2010;12:557-67.
60. Mwangi B, Wu MJ, Cao B et al. Individualized prediction and clinical staging of bipolar disorders using neuroanatomical biomarkers. *Biol Psychiatry Cogn Neurosci Neuroimaging* 2016;1:186-94.
61. Lyoo IK, Sung YH, Dager SR et al. Regional cerebral cortical thinning in bipolar disorder. *Bipolar Disord* 2006;8:65-74.
62. Strakowski SM, DelBello MP, Zimmerman ME et al. Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. *Am J Psychiatry* 2002;159:1841-7.
63. Bechdolf A, Wood SJ, Nelson B et al. Amygdala and insula volumes prior to illness onset in bipolar disorder: a magnetic resonance imaging study. *Psychiatry Res* 2012;201:34-9.
64. Fornito A, Malhi GS, Lagopoulos J et al. In vivo evidence for early neurodevelopmental anomaly of the anterior cingulate cortex in bipolar disorder. *Acta Psychiatr Scand* 2007;116:467-72.

65. Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. *J Affect Disord* 2009;113:1-20.
66. El-Badri SM, Ashton CH, Moore PB et al. Electrophysiological and cognitive function in young euthymic patients with bipolar affective disorder. *Bipolar Disord* 2001;3:79-87.
67. Robinson LJ, Ferrier IN. Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. *Bipolar Disord* 2006;8:103-16.
68. Kozicky JM, Torres IJ, Silveira LE et al. Cognitive change in the year after a first manic episode: association between clinical outcome and cognitive performance early in the course of bipolar I disorder. *J Clin Psychiatry* 2014;75:e587-93.
69. Rosa AR, Magalhães PV, Czepielewski L et al. Clinical staging in bipolar disorder: focus on cognition and functioning. *J Clin Psychiatry* 2014;75:e450-6.
70. Reinares M, Papachristou E, Harvey P et al. Towards a clinical staging for bipolar disorder: defining patient subtypes based on functional outcome. *J Affect Disord* 2013;144:65-71.
71. Grande I, Magalhães PV, Chendo I et al. Staging bipolar disorder: clinical, biochemical, and functional correlates. *Acta Psychiatr Scand* 2014;129:437-44.
72. Wade AA, Kuschke RH, Wood LA et al. Serological observations in patients suffering from acute manic episodes. *Hum Psychopharmacol* 2002;17:175-9.
73. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. *Int J Neuropsychopharmacol* 2009;12:447-58.
74. Kapczinski F, Fernandes BS, Kauer-Sant'Anna M et al. The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers. *Acta Neuropsychiatrica* 2009;21:272-4.
75. Andreazza AC, Kapczinski F, Kauer-Sant'Anna M et al. 3-nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. *J Psychiatry Neurosci* 2009;34:263-71.
76. Reininghaus EZ, Lackner N, Birner A et al. Extracellular matrix proteins matrix metalloproteinase 9 (MMP9) and soluble intercellular adhesion molecule 1 (sICAM-1) and correlations with clinical staging in euthymic bipolar disorder. *Bipolar Disord* 2016;18:155-63.
77. Moylan S, Maes M, Wray NR et al. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. *Mol Psychiatry* 2013;18:595-606.
78. Martino DJ, Samamé C, Marengo E et al. A critical overview of the clinical evidence supporting the concept of neuroprogression in bipolar disorder. *Psychiatry Res* 2016;235:1-6.
79. Malhi GS, Berk M. Diagnosing bipolar disorder: defining thresholds and setting boundaries. *Aust N Z J Psychiatry* 2014;48:500-4.
80. Kupfer DJ. Neuroscience-informed nosology in psychiatry: are we there yet? *Asian J Psychiatry* 2014;7:2-3.
81. Bauer IE, Gálvez JF, Hamilton JE et al. Lifestyle interventions targeting dietary habits and exercise in bipolar disorder: a systematic review. *J Psychiatr Res* 2016;74:1-7.
82. Bechdolf A, Nelson B, Cotton SM et al. A preliminary evaluation of the validity of at-risk criteria for bipolar disorders in help-seeking adolescents and young adults. *J Affect Disord* 2010;127:316-20.
83. Bechdolf A, Ratheesh A, Wood SJ et al. Rationale and first results of developing at-risk (prodromal) criteria for bipolar disorder. *Curr Pharm Des* 2012;18:358-75.
84. Leopold K, Ritter P, Correll CU et al. Risk constellations prior to the development of bipolar disorders: rationale of a new risk assessment tool. *J Affect Disord* 2012;136:1000-10.
85. Berk M, Dodd S, Callaly P et al. History of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder. *J Affect Disord* 2007;103:181-6.
86. Malhi GS, Chengappa KN, Gershon S et al. Hypomania: hype or mania? *Bipolar Disord* 2010;12:758-63.
87. Axelson D, Goldstein B, Goldstein T et al. Diagnostic precursors to bipolar disorder in offspring of parents with bipolar disorder: a longitudinal study. *Am J Psychiatry* 2015;172:638-46.
88. Birmaher B. Bipolar disorder in children and adolescents. *Child Adolesc Ment Health* 2013;18.
89. Post RM, Chang K, Frye MA. Paradigm shift: preliminary clinical categorization of ultrahigh risk for childhood bipolar disorder to facilitate studies on prevention. *J Clin Psychiatry* 2013;74:167-9.
90. Goodman M, Hazlett EA, New AS et al. Quieting the affective storm of borderline personality disorder. *Am J Psychiatry* 2009;166:522-8.
91. Post RM, Altshuler LL, Kupka R et al. More childhood onset bipolar disorder in the United States than Canada or Europe: implications for treatment and prevention. *Neurosci Biobehav Rev* 2017;74:204-13.
92. Conus P, Berk M, Cotton SM et al. Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: an 8-week randomised controlled trial. *Eur Psychiatry* 2015;30:975-82.
93. Nierenberg AA, McElroy SL, Friedman ES et al. Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder. *J Clin Psychiatry* 2016;77:90-9.
94. Murray G, Leitan ND, Berk M et al. Online mindfulness-based intervention for late-stage bipolar disorder: pilot evidence for feasibility and effectiveness. *J Affect Disord* 2015;178:46-51.
95. Macneil CA, Hallam K, Conus P et al. Are we missing opportunities for early intervention in bipolar disorder? *Expert Rev Neurother* 2012;12:5-7.
96. Kessing LV, Hansen HV, Hvenegaard A et al. Treatment in a specialised out-patient mood disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. *Br J Psychiatry* 2013;202:212-9.
97. Bertelsen M, Jeppesen P, Petersen L et al. Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. *Arch Gen Psychiatry* 2008;65:762-71.
98. Vieta E, Torrent C. Functional remediation: the pathway from remission to recovery in bipolar disorder. *World Psychiatry* 2016;15:288-9.
99. Macneil CA, Hasty M, Cotton S et al. Can a targeted psychological intervention be effective for young people following a first manic episode? Results from an 18-month pilot study. *Early Interv Psychiatry* 2012;6:380-8.
100. Macneil CA, Hasty MK, Berk M et al. Psychological needs of adolescents in the early phase of bipolar disorder: implications for early intervention. *Early Interv Psychiatry* 2011;5:100-7.
101. Berk L, Jorm AF, Kelly CM et al. Development of guidelines for caregivers of people with bipolar disorder: a Delphi expert consensus study. *Bipolar Disord* 2011;13:556-70.
102. Malla A, Iyer S, McGorry P et al. From early intervention in psychosis to youth mental health reform: a review of the evolution and transformation of mental health services for young people. *Soc Psychiatry Psychiatr Epidemiol* 2016;51:319-26.
103. O'Neil A, Jacka FN, Quirk SE et al. A shared framework for the common mental disorders and non-communicable disease: key considerations for disease prevention and control. *BMC Psychiatry* 2015;15:15.

DOI:10.1002/wps.20441